Evidence map›Paper›PMID 31620357›Full record

ArticleFrontiers in oncology2019

Unraveling Heparan Sulfate Proteoglycan Binding Motif for Cancer Cell Selectivity.

Jlenia Brunetti, Giulia Riolo, Lorenzo Depau, Elisabetta Mandarini, Andrea Bernini, Evgenia Karousou, Alberto Passi, Alessandro Pini, Luisa Bracci, Chiara Falciani

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Jlenia BrunettiDepartment of Medical Biotechnologies, University of Siena, Siena, Italy.
Giulia RioloDepartment of Medical Biotechnologies, University of Siena, Siena, Italy.
Lorenzo DepauDepartment of Medical Biotechnologies, University of Siena, Siena, Italy.
Elisabetta MandariniDepartment of Medical Biotechnologies, University of Siena, Siena, Italy.
Andrea BerniniDepartment of Biotechnology, Chemistry and Pharmacy, University of Siena, Siena, Italy.
Evgenia KarousouDepartment of Medicine and Surgery, University of Insubria, Varese, Italy.
Alberto PassiDepartment of Medicine and Surgery, University of Insubria, Varese, Italy.
Alessandro PiniDepartment of Medical Biotechnologies, University of Siena, Siena, Italy.
Luisa BracciDepartment of Medical Biotechnologies, University of Siena, Siena, Italy.
Chiara FalcianiDepartment of Medical Biotechnologies, University of Siena, Siena, Italy.
University of Siena · ITUniversity of Insubria · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Membrane heparan sulfate proteoglycans (HSPG) regulate cell proliferation, migration, and differentiation and are therefore considered key players in cancer cell development processes. Here, we used the NT4 peptide to investigate how the sulfation pattern of HSPG on cells drives binding specificity. NT4 is a branched peptide that binds the glycosaminoglycan (GAG) chains of HSPG. It has already been shown to inhibit growth factor-induced migration and invasiveness of cancer cells, implying antagonist binding of HSPG. The binding affinity of NT4 with recombinant HSPG showed that NT4 bound glypican-3 and -4 and, with lower affinity, syndecan-4. NT4 binding to the cancer cell membrane was inversely correlated with sulfatase expression. NT4 binding was higher in cell lines with lower expression of SULF-1 and SULF-2, which confirms the determinant role of sulfate groups for recognition by NT4. Using 8-mer and 9-mer heparan sulfate (HS) oligosaccharides with analog disaccharide composition and different sulfation sites, a possible recognition motif was identified that includes repeated 6-O-sulfates alternating with N- and/or 2-O-sulfates. Molecular modeling provided a fully descriptive picture of binding architecture, showing that sulfate groups on opposite sides of the oligosaccharide can interact with positive residues on two peptide sequences of the branched structure, thus favoring multivalent binding and explaining the high affinity and selectivity of NT4 for highly sulfated GAGs. NT4 and possibly newly selected branched peptides will be essential probes for reconstructing and unraveling binding sites for cancer-involved ligands on GAGs and will pave the way for new cancer detection and treatment options.

Indexed as

heparan sulfate proteoglycansoligosaccharidepeptidesulfatasetumor targeting

Identifiers

PMID31620357
PMCPMC6759624
OpenAlexW2969861911

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.